BioSpace News Archive

New location provides pharmacy services and home delivery to its growing base of hospice patients in the Bay Area and Western US.

NSF Funds Neocortex , a Groundbreaking AI Supercomputer, at PSC The National Science Foundation awarded $5 million to the Pittsburgh Supercomputing Center to build Neocortex, an AI supercomputer that will introduce revolutionary technologies

After encouraging preliminary results in the treatment of critically-ill COVID-19 patients at a military hospital in the United States and fourteen other hospitals in Europe, the Department of Defense has selected the Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) as one of its main interventions in a pivotal, US-based randomized controlled trial. Financial support for the multi-center trial will be provided

The creators of the BioAssured™ Process and BioAssured Certification ™ have announced a strategic partnership with Orlando headquartered, Massey Services. Serving over 650,000

EKKDA Research, LLC, an ophthalmic-focused research and development company based in Kingsland, Texas is pleased to announce a sales-distribution agreement has been reached with OCuSOFT Inc.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (“Reducer”) and Tiara™ (“Tiara”) program will be featured at two industry conferences this month.

Bio Conscious Technologies Inc. (“Bio Conscious”) a Prevention-as-a-Service™ technology company using machine learning to predict and manage chronic diseases such as diabetes, is announcing that it has completed an in-house, in silico study to test its Diabits AI algorithm.

A Community Event sponsored by the Gunnison County Consortium on June 24th will focus on the Gunnison Valley’s effort to address substance use disorder and the opioid crisis.

- Tumor Shrinkage and Related Clinical Responses Observed in KEYNOTE-890 in Heavily Pretreated mTNBC Patients Supports Moving to a First-Line Treatment

Sekisui Diagnostics announces it has received US Food and Drug Administration (FDA) 510(k) clearance and CLIA Waiver for the OSOM® Ultra Plus Flu A&B Test.